Topnav

Archive | Oncology

About biosimilars

The expiry of the patent protection of many biological medicines has paved the way for greater access to these life-saving treatments, through the production of biosimilar medicines. Biological drugs have provided success in the treatment of many cancers, including melanomas and leukemias; rheumatic conditions; arthritis; diabetes; and asthma. Biological medicines are made up of complex […]

Continue Reading · 0

Progress in the treatment of advanced melanoma

Dr Marc Maurel In the November 2010 edition of the Medical Chronicle, Dr Samuel Fourie outlined new developments in the treatment of metastatic melanoma. Over the last two years, these treatments have been refined and joined by new molecules, which has changed the paradigm of melanoma management. Traditionally, metastatic melanoma has been a difficult disease to […]

Continue Reading · 0

Management of Hepatocellular Cancer

Dr Daniel Rens Following on from the September edition forum article on hepatocellular carcinoma (HCC), which looked at the clinical presentation and diagnosis of the condition, this article focuses on its treatment and management. HCC is the most common form of primary liver cancer, and is responsible for approximately 500 000 global deaths per year. […]

Continue Reading · 0

Glioma Incidence and Epidemiology

Dr Louis Kathan Gliomas and primary CNS lymphomas are the most frequent primary malignant brain tumours in adults. (Meningiomas and pituitary adenomas are also frequent, but in contrast to the aforementioned, these are extraparenchymatous tumours and their treatments are mainly surgical or endocrinological.) The incidence of malignant glioma is six cases/100 000/year with the peak […]

Continue Reading · 0

Stem Cell Transplantation in Myeloma

Dr Devan Moodley A decade has elapsed and it has become established that stem cell transplantation is the standard of care for myeloma patients eligible for autologous stem cell transplantation. It was the Francophone du Myélome (IFM) trial that first demonstrated the benefit of autologous transplantation over conventional therapy in myeloma sufferers. Since then, this […]

Continue Reading · 0

Bladder Preservation in Invasive Bladder Cancer

Dr Marc Maurel Bladder cancer is the most common cancer affecting the urinary tract. Transitional cell (urothelial) carcinoma accounts for about 90% of cases. The average age at presentation is approximately 70 years and known predisposing factors include smoking and occupational carcinogen exposure. Prognosis The early stage of bladder cancer – nonmuscle invasive disease – […]

Continue Reading · 0

Difficulties in Managing Epithelial Ovarian Cancer

Dr Daniel Rens Mortality from ovarian cancer has remained high, despite efforts to improve prognosis, through early detection, advances in surgical techniques and more effective chemotherapy. There has been an ongoing lack of effective screening tools for early disease, resulting in a high percentage of patients already suffering from advanced stage disease at diagnosis. Ovarian […]

Continue Reading · 0

Treatment and Prognosis of Osteosarcoma

Dr Louis Kathan Primary bone tumours are rare, accounting for <0,2% of malignant tumours registered. Osteosarcoma is the most common malignant bone tumour in adolescence and childhood (it accounts for over 50% of primary bone tumours in patients <20 years of age), and is the sixth leading cancer in children >15 years. The age distribution […]

Continue Reading · 0